The mean P-2-microglobulin level in serum (3,362 ± 2,494 ,ug/liter) for 76 leprosy patients, including 9 borderline-tuberculoid, 8 borderline-borderline, 9 borderline-lepromatous, and 16 lepromatous-lepromatous patients and 34 patients with type I or type Il lepra reactions, was significantly higher (P < 0.001) than that (2,122 ± 1,844 ,ug/liter) for 35 normal subjects. It P-2-Microglobulin (P-2-m), a nonglycosylated polypeptide associated with HLA antigens and also found in serum, has a marked amino acid sequence homology with the C3H domain of immunoglobulin G (IgG) (3). Elevated 1-2-m levels in serum in autoimmune diseases, several advanced malignant conditions, and chronic granulomatous and lymphoproliferative disorders suggest the association of 1-2-m with polyclonal or monoclonal activation of immune system. Patients in remission rarely show raised ,B-2-m levels in their sera (14) . It is raised in sera of patients with altered glomerular filtration also, as with early rejection of kidney transplants (4, 8, 9, 19, 20, 24 One serum sample was collected from each subject. Two samples each were taken from the 34 reactional patients: one sample was taken at the onset of reaction before steroid therapy was begun, and the subsequent sample was taken after the clinical remission of reaction and withdrawal of steroids.
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1-2-m levels were determined by a competitive enzyme immunoassay (ABS-75103, Pharmacia Diagnostics, Uppsala, Sweden) in test and control sera. The data were grouped, mean and standard deviations were determined, and a statistical significance test was performed.
The mean 13-2-m levels in serum for control and leprosy patients were 2,122 1,844 Ftg/liter (range, 252 to 6,800 ,ug/liter) and 3,362 2,494 ,ug/liter (range, 210 to 11,000 ptg/liter), respectively. The difference was statistically highly significant (t = 2.83; P < 0.001) (Fig. 1 ). Mean 13-2-m levels in serum for 9 BT, 8 BB, 9 BL, and 16 LL patients were 3,173 ± 899, 2,708 ± 1,820, 2,130 1,472, and 1,813 ± 1,391 ,ug/liter, respectively. In the sera of the three histoid leprosy patients, 1-2-m levels were 2,080, 1,480, and 1,760 ,uglliter (Fig. 2) from tuberculoid to the lepromatous end (Fig. 2) can be explained by the findings of Revillard, who observed a very high ,B-2-m level in serum (4,070 ± 1,390 ,ug/liter) for patients with chronic active hepatitis and a low level for patients with chronic persistent hepatitis (2,240 ± 790 ,ug/liter). He related the high level of 13-2-m in serum observed in patients with chronic active hepatitis to the degree of lymphocyte infiltration of the liver and related the lower level in patients with chronic persistent hepatitis to lesser lymphocyte infiltration. A heavy lymphocytic infiltration is found in the dermal epitheloid cell granulomata of patients with tuberculoid leprosy, which is usually scanty in the histiocytic cell granulomata within the dermis in lepromatous patients (11) .
Thus, the high 1-2-m levels observed in the sera of the BT leprosy patients may be due to the extensive dermal lymphocytic infiltration.
During any immune response (e.g., BT leprosy), substantial 1-2-m is produced locally in a lymph node, the spleen, or bone marrow, which in turn might be able to effect lymphocytes in the neighborhood and convert these lymphocytes from their nascent forms into suppressor cells (5) . Suppressor cell activity is associated with tuberculoid leprosy patients (6 (Fig. 3) . The mean concentration of ,B-2-m in serum was higher in type Il reactions than in type I reactions ( Table  1) .
The mean 1-2-m level in serum for Indian subjects (2,122 ,ug/liter) is comparable to that (2 mg/liter) observed earlier (13) . The high (6,800 lxg/liter) level observed in the serum of one normal Indian female is not surprising. Similar high values in normal individuals, despite adequate renal functions, have been previously described (20) .
The elevation of 1-2-m levels in serum has been observed in leprosy patients for the first time. Revillard et al. (20) demonstrated raised 13-2-m levels in the sera of patients with sarcoidosis and Crohn's disease and suggested an association of polyclonal activation of B-lymphocytes with the ,B-2-m level in serum. They also showed increased 1-2-m levels in the sera of patients with autoimmune diseases. Leprosy is a chronic granulomatous disease. Increased immunoglobulin levels in serum and various autoantibodies are found in these patients, symptoms which indicate polyclonal B-cell activation (23) .
An alternative explanation of raised 13-2-m levels in sera of leprosy patients may be the presence of cold-reacting lymphocytotoxic antibodies in their sera (22) , which does not correlate with any of the HLA antigens of the donor cell (S. Naik, B. Kumar, and S. Sehgal, 12th Int. Lepr. Cong., abstr. no. 11, p. 95, 1984) . Also, raised levels of the IgM class of antibodies against 13-2-m levels in the sera of systemic lupus erythematosus and leprosy patients have been found (1) . 21, 1985 12 F and lowers the 1-2-m level in serum (20) . Similar decreases have been observed in 13-2-m levels in the sera of 19 of 34 (55.5%) patients with leprosy reactions after treatment with prednisolone (Fig. 3) .
The rise of the 13-2-m level in serum during the reactional phase of the disease needs explanation. During erythemanodusum-leprosum, there is deposition of immune complexes and acute-phase reactants extravascularly at the site of small granulomas (15) (16) (17) (8) demonstrated a rapid fall of 13-2-m and C-reactive protein levels in the sera of some patients of Hodgkin's disease or non-Hodgkin's lymphoma after radio-or chemotherapy, which signified remission of the illnesses. Earlier, we demonstrated raised CRP level in serum during and after remission of erythema-nodusum-leprosum (23) .
Estimation of 13-2-m levels in serum offered an alternative method for the assessment of glomerular filtration rate. Lepromatous leprosy patients showed proliferative glomerulonephritis, amyeloidosis, and renal tubular changes (12) . Proteinuria and low clearance of creatinine have been found in nonlepromatous and lepromatous cases (18) . Proteinuria, edema, and other biochemical abnormalities have also been observed in the reactional phase of leprosy (25) . It in these patients (26) . Thus, another possible explanation for the high P-2-m levels in the sera of leprosy patients during reaction is the involvement of glomerulin, which warrants a future study of ,3-2-m levels in the urine of these patients. Bajaj et al. (2) have demonstrated impairment of renal function in leprosy patients during reaction and also during quiescent phase.
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